Module 1—Key Concepts in Oncology: Angiogenesis as a Therapeutic Target

Module 2—Targeting Angiogenesis in Colorectal Cancer

Module 3—Targeting Angiogenesis in Ovarian Cancer

Module 4—Targeting Angiogenesis in Breast Cancer

Module 5—Targeting Angiogenesis in Non-Small Cell Lung Cancer

Module 6—Targeting Angiogenesis in Glioblastoma

SUBTOPICS

• Assessing the role of antiangiogenic therapy: An expert appraisal
• Approaches for optimizing outcomes: From patient selection to duration of therapy
• Practical considerations in patient management: A focus on safe

After successful completion of this educational activity, participants should be able to:

• Describe the rationale for targeting angiogenesis, mechanisms of action for various related therapies, and current status of biomarkers for patient selection
• Discuss the most recent clinical practice guidelines regarding antiangiogenic agents, including strategies for optimal patient management based on clinical and molecular features
• Compare and contrast the efficacy and tolerability of various antiangiogenic strategies in the management of solid tumors based on data from recent clinical studies

In accordance with the ACCME standards for Commercial Support, educational activities sponsored by prIME Oncology must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in a prIME Oncology–sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Dr Van Cutsem has disclosed that he has performed contracted research for Amgen Inc.; F. Hoffmann-La Roche Ltd; Merck Serono International S.A.; Novartis Pharmaceuticals Corporation; Pfizer Inc; and sanofi-aventis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Berry has disclosed that he has received fees for non-CME services from Amgen Inc.; F. Hoffmann-La Roche Ltd; and sanofi-aventis. He has also received speaking honoraria for accredited CME events supported by Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd; and sanofi-aventis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Colombo has disclosed that she has received consulting fees from Amgen Dompe; Bristol- Myers Squibb; F. Hoffmann-La Roche Ltd; and sanofi-aventis. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Kim has disclosed that he has received consulting fees from Bayer HealthCare Corporation; Boehringer Ingleheim Pharmaceuticals, Inc.; Genentech; and Onyx Pharmaceuticals Inc. He has also performed contracted research for Eli Lilly and Company. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gligorov has disclosed that he has received consulting fees from F. Hoffmann-La Roche Ltd and sanofi-aventis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wick has disclosed that he has received consulting fees from Antisense Pharma; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; and Magforce. He has also received fees for non-CME services from F. Hoffmann-La Roche Ltd and MSD. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.


The employees of prIME Oncology have disclosed:
Bojana Pajk, MD, MSc (clinical) – no relevant financial relationships to disclose
Trudy Stoddert, ELS (editorial) – no relevant financial relationships with commercial supporters of this activity
Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships with commercial supporters of this activity

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.